Analyst Jason Butler of JMP Securities reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $7.00. Jason ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of ...

Urogen's UGN-102 presents a $5B market opportunity for bladder cancer treatment, despite risks. Read more about URGN stock ...

United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. Check out why I rate UTHR ...

Shares of Altimmune (NASDAQ:ALT) rallied 30% in afternoon trading after the company issued several business updates along ...

The high-profile Asia-Pacific Economic Cooperation summit in Lima has thrust one of the world’s least popular presidents into ...

Recent quality and operational issues at Smiths, which originated before it was purchased, greatly reduced ICU’s gross margin after the acquisition. These issues have required additional spending to ...

Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, ...

The county reported its highest detainee death count in decades, including multiple suicides that reveal deep institutional ...

His positions on the economy and illegal immigration, plus a sense that a strong leader was needed are some of the reasons.

Those who sign up for original Medicare typically add Part D prescription drug coverage and sometimes a "Medigap" ...